Results 31 to 40 of about 674,291 (325)
Reversal of Pulmonary Hypertension in a Patient with Chronic Mountain Sickness after Relocation to Low Altitude [PDF]
Journal of Clinical and Diagnostic Research, 2021 Long-term high altitude residence can be complicated by development of Chronic Mountain Sickness (CMS) characterised by excessive erythrocytosis and neurological symptoms.
Abdirashit Maripov +4 more
doaj +1 more source
Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension [PDF]
, 2018 Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models.
Alastalo +23 more
core +4 more sources
Pulmonary Circulation, 2022 Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions ...
Abdullah M. Aldalaan +7 more
doaj +1 more source
Current Problems in Cardiology, 2004 Pulmonary hypertension, in its simplest sense, is elevation of the pulmonary artery pressure above normal. A multitude of diseases may increase the pulmonary artery pressure and result in right ventricular dysfunction. The treatments of pulmonary hypertension are as varied as its causes.
Vallerie V, McLaughlin, Stuart, Rich
openaire +2 more sources
A Case Report of Systemic Sclerosis Complicated by Biventricular Heart Failure, Pulmonary Hypertension and Review of Literature [PDF]
, 2017 Background: Systemic sclerosis (SSc) is an autoimmune connective tissue disorder whose aetiology is not fully understood. Skin fibrosis and visceral organs involvement are the hallmarks, and the heart could be disproportionately or subtly involved ...
Akinboro AO +3 more
core +1 more source
Macitentan in daily clinical practice: A single centre, 1-year experience
Pulmonology, 2018 The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events.
S. Cadenas-Menéndez +5 more
doaj +3 more sources
Arthritis Research & Therapy, 2023 Background Patients with systemic sclerosis (SSc) are frequently affected by iron deficiency, particularly those with pulmonary hypertension (PH). The first data indicate the prognostic importance of hypochromic red cells (% HRC) > 2% among patients with
Panagiota Xanthouli +14 more
doaj +1 more source
Pulmonary Circulation, 2019 A 36-year-old woman presented with recurrent pulmonary emboli (PE) despite oral anticoagulation. She was a type I diabetic with severe gastroparesis requiring insertion of multiple long-term peripherally inserted central catheters (PICC) over a 10-year ...
Abigail Masding +10 more
doaj +1 more source
Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1 [PDF]
, 2018 Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined.
Chen, Jiwang +6 more
core +1 more source
The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients
BMC Pulmonary Medicine, 2019 Background Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH).
Iain Armstrong +6 more
doaj +1 more source